Presentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 2022
News
October 6, 2022
The excellent phase l/lla clinical data of FG001 in aggressive brain cancer will be presented by Principal Investigator and Chief Surgeon Jane Skjøth-Rasmussen at the European Congress of Neurosurgery in Belgrade, facilitated by the European Association of Neurosurgical Societies (EANS).
The purpose of the trial was to investigate FG001 for intraoperative visualization of malignant glioma in patients scheduled for neurosurgery. The full abstract can be found here.
Based on the promising clinical data, FG001 is advanced into a phase IIb trial in aggressive brain cancer where the top line result is expected in H1 2023.